Personalized Medicine for Non–Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing

2012 ◽  
Vol 13 (5) ◽  
pp. 334-339 ◽  
Author(s):  
Andre L. Moreira ◽  
Raymond H. Thornton
2015 ◽  
Vol 75 (12) ◽  
pp. 2416-2425 ◽  
Author(s):  
Núria Buil-Bruna ◽  
Tarjinder Sahota ◽  
José-María López-Picazo ◽  
Marta Moreno-Jiménez ◽  
Salvador Martín-Algarra ◽  
...  

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2110 ◽  
Author(s):  
Samira Shojaee ◽  
Patrick Nana-Sinkam

Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.


2016 ◽  
Vol 11 (10) ◽  
pp. S192-S193
Author(s):  
Liliana Fernandez ◽  
Juan F. Henao ◽  
Luz F. Sua ◽  
Valeria Zuñiga ◽  
Leidys Gutiérrez

1996 ◽  
Vol 7 (4) ◽  
pp. 363-385 ◽  
Author(s):  
Glenwood D. Goss ◽  
Simone Dahrouge ◽  
Catherine A. Lochrin

Sign in / Sign up

Export Citation Format

Share Document